Hematology procedure guide

Stem cell transplant in India with autologous, allogeneic, and donor-source planning

Stem cell transplant restores blood-forming stem cells after intensive treatment or replaces diseased marrow with healthy donor cells. Patients may hear terms such as autologous transplant, allogeneic transplant, peripheral blood stem cell transplant, bone marrow transplant, cord blood transplant, haploidentical transplant, conditioning, engraftment, and GVHD. This guide explains the planning pathway for international patients comparing India for hematology treatment.

How is stem cell transplant planned?

Stem cell transplant planning starts with the diagnosis, disease status, previous treatment response, organ fitness, infection status, and donor source. Autologous transplant uses the patient own stem cells after collection, while allogeneic transplant uses a donor. The team decides conditioning intensity, stem cell source, admission timing, isolation needs, transfusion plan, infection prevention, GVHD prevention, and follow-up schedule before travel dates are finalized.

Upload reports Request second opinion

Candidate fit

Who this procedure may suit

Autologous transplant candidates

Eligible myeloma, lymphoma, germ cell tumor, or selected autoimmune patients may use their own collected stem cells after high-dose therapy.

Allogeneic transplant candidates

High-risk leukemia, MDS, aplastic anemia, inherited blood disorders, or relapsed disease may need donor stem cells.

Patients with donor options

Matched sibling, matched unrelated, haploidentical family, or cord options are compared for allogeneic transplant.

Fit enough for intensive therapy

Heart, lung, kidney, liver, infection, nutrition, and performance status must support the planned conditioning regimen.

What it treats

Conditions and symptoms usually reviewed

Multiple myeloma

Autologous stem cell transplant can be part of treatment for eligible patients after induction therapy and stem cell collection.

Leukemia and MDS

Allogeneic transplant may offer curative potential in selected high-risk or relapsed disease when donor match and remission status are suitable.

Lymphoma

Autologous or allogeneic transplant may be considered depending on lymphoma type, relapse timing, response, and previous therapy.

Non-cancer blood disorders

Aplastic anemia, thalassemia, sickle cell disease, and immune deficiencies may be reviewed by specialized hematology teams.

Procedure approach

Techniques, devices, and treatment choices

Technique choice can affect cost, hospital stay, recovery speed, risk profile, and follow-up requirements.

Stem cell sources

The source determines collection method, matching needs, recovery pattern, and risks.

Peripheral blood stem cells

Stem cells are collected from blood using apheresis after mobilization medicines or donor preparation.

Bone marrow harvest

Stem cells are collected from marrow under anesthesia in selected donor or disease settings.

Cord blood transplant

Umbilical cord blood can be used in selected cases but has unique dose, matching, and engraftment considerations.

Transplant approaches

Approach choice is diagnosis-specific and risk-specific.

Autologous SCT

The patient own cells rescue marrow after high-dose chemotherapy; there is no donor GVHD, but relapse remains possible.

Allogeneic SCT

Donor cells can create a graft-versus-cancer effect but require immune suppression and GVHD monitoring.

Reduced-intensity transplant

Lower-intensity conditioning may suit selected older or less-fit patients, but relapse and graft risks must be discussed.

Reports before planning

What to share before choosing a hospital

Reports help doctors confirm whether the procedure is suitable and what can change the treatment plan after arrival.

1 Diagnosis, marrow report, biopsy, flow cytometry, cytogenetics, molecular markers, risk group, and disease status.
2 Prior treatment summary with drug names, cycles, response, complications, and current remission or active disease evidence.
3 HLA typing for patient and donors, donor relation, donor age, blood group, and infectious screening if available.
4 Stem cell collection records if autologous collection has already happened.
5 Heart, lung, kidney, liver, dental, fertility, nutrition, and performance-status assessment.
6 Infection records including fungal infection, CMV, EBV, hepatitis, HIV, TB, fever admissions, and catheter infections.
7 PET-CT, CT, MRI, or disease-specific imaging used to confirm response before transplant.
8 Current medicines, transfusion history, allergies, central line history, and caregiver availability.

Preparation

How patients usually prepare before travel

Name the transplant type

Patients should know whether the plan is autologous, allogeneic, haploidentical, cord, unrelated donor, or reduced-intensity.

Confirm disease status

Many transplants require remission or controlled disease before admission, so latest marrow or scan results matter.

Screen infections and organs

A hidden infection or organ weakness can delay transplant or increase ICU risk.

Plan caregiver role

A caregiver helps with hygiene, food safety, symptom reporting, medicines, and emotional support during long recovery.

Hospital stay

What may happen during admission in India

Workup and collection

The center completes organ tests, donor or autologous collection steps, line placement, and final consent.

Conditioning regimen

Chemotherapy, and sometimes radiation, is given to prepare the marrow and immune system.

Stem cell infusion

Stem cells are infused through a vein, followed by close monitoring until blood counts recover.

Post-transplant monitoring

Fever, mouth sores, diarrhea, transfusions, drug levels, GVHD, and infection markers are monitored daily during admission.

Recovery

Recovery and follow-up milestones

Engraftment phase

The lowest count period carries the greatest infection and transfusion need, with count recovery watched closely.

First 100 days

Frequent visits monitor infections, GVHD, drug levels, organ function, fatigue, appetite, and disease response.

Months 3-12

Immune recovery, vaccinations, strength, school or work return, and infection precautions are individualized.

Beyond one year

Long-term care monitors relapse, late organ effects, fertility, bone health, chronic GVHD, and secondary cancers.

Risks and safety questions

What to discuss with the treating team

Infection during low counts

Blood counts can fall very low after conditioning, creating serious infection risk.

Fever needs urgent review.

GVHD in donor transplant

Donor immune cells can affect skin, liver, gut, lungs, or other organs.

Not a risk in autologous transplant.

Mucositis and nutrition issues

Mouth sores, diarrhea, poor intake, and weight loss can occur after conditioning.

Dietitian support helps.

Organ toxicity

Chemotherapy and immune medicines can affect liver, kidneys, lungs, heart, fertility, and endocrine health.

Baseline tests guide risk.

Disease relapse

Some diseases can return despite transplant, especially if disease control was incomplete.

Response monitoring continues.

India advantages

Why international patients may compare India

Clear terminology comparison

Indian hematology teams can help families understand BMT, SCT, autologous, allogeneic, haploidentical, and CAR-T differences.

Specialized transplant units

Major centers provide isolation rooms, transplant nursing, transfusion support, infection care, ICU backup, and hematopathology.

Cost-effective advanced care

India can be competitive for transplant pathways when estimates clearly show donor, processing, medicines, infections, and long-stay assumptions.

Long-trip coordination

Virello can support visa letters, housing near the center, caregiver logistics, infection-safe transport, and follow-up records.

Cost range and variables

What can change the estimate in India

India planning range

Stem cell transplant often ranges around $22,000-$65,000+, with allogeneic, unrelated donor, haploidentical, infection, ICU, and longer stay increasing cost.

Final estimate is diagnosis-specific.

Donor source

Autologous collection, sibling donor, haploidentical donor, unrelated donor, and cord blood all have different processing and medicine costs.

Ask for the source in writing.

Conditioning intensity

Myeloablative, reduced-intensity, or high-dose chemotherapy regimens differ by drug cost, toxicity, and monitoring.

Protocol drives risk.

City tier

Delhi NCR, Mumbai, Chennai, Bangalore, Hyderabad, and Gurgaon offer broad SCT depth; selected Ahmedabad, Pune, Coimbatore, and other centers may suit lower-risk pathways.

Complex allogeneic cases need deep backup.

Post-discharge cost

Labs, drug levels, antimicrobials, immunosuppression, transfusions, scans, and accommodation continue after admission.

Plan beyond discharge.

Hospital selection

How to compare hospitals

Accredited transplant workflow

Look for structured SCT protocols, isolation rooms, trained nurses, hematology coverage, and emergency escalation.

Process quality matters.

Apheresis and processing

Stem cell collection, processing, storage, and infusion should be well coordinated.

Logistics can delay care.

Infection and ICU backup

Fungal infection, sepsis, respiratory failure, and bleeding need rapid support.

Backup should be visible.

Follow-up system

Patients need lab schedule, drug-level checks, remote communication, vaccination plan, and relapse monitoring.

SCT recovery is long.

Doctor selection

How to compare doctors

Transplant hematologist

Ask why SCT is recommended, which type, what conditioning, what donor source, and what alternatives exist.

Infection specialist access

A center experienced with transplant infections can reduce delays and complications.

Infections are common.

Pediatric or adult fit

Children and adults need different dosing, support, caregiver counselling, and long-term monitoring.

Choose age-specific experience.

Communication after return

The doctor should provide clear instructions for fever, GVHD symptoms, labs, medicines, and vaccination follow-up.

Home care must be structured.

Questions

Common questions

What is the difference between stem cell transplant and bone marrow transplant?

Stem cell transplant is the broader term. Stem cells can come from blood, bone marrow, or cord blood. Bone marrow transplant is a common older term patients still use.

What is the cost of stem cell transplant in India?

A broad range is about $22,000-$65,000+, depending on transplant type, donor source, conditioning, infections, ICU, transfusions, city, and stay length.

Is autologous transplant safer than allogeneic transplant?

Autologous transplant avoids donor GVHD, but it may not be suitable for all diseases. Allogeneic transplant has donor immune effects but higher immune and infection risks.

How long does engraftment take?

Engraftment timing varies by stem cell source, conditioning, disease, and patient factors. The team tracks white cells, platelets, and clinical recovery.

Can family members donate stem cells?

Yes, if HLA matching and donor health are acceptable. Haploidentical family donors may be considered in selected centers when fully matched donors are unavailable.

Can I return home immediately after discharge?

Usually no. Patients need early follow-up near the center after discharge because infection, GVHD, low counts, or medicine issues can occur.

Can stem cell transplant be done for autoimmune disease?

Selected autoimmune uses exist in specialized settings, but suitability depends on disease, prior treatments, protocol, risk, and center experience.

Can Virello help compare SCT and CAR-T?

Yes. Virello can help compare disease fit, eligibility, cost, hospital capability, stay length, and follow-up needs for SCT and CAR-T pathways.

Continue planning